Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,415 GBX | +15.98% | +31.02% | +108.09% |
Apr. 10 | 4basebio to supply synthetic DNA for mRNA vaccine program | AN |
Apr. 10 | 4Basebio plc Announces the Supply of Its opDNA? DNA Products into Tier 1 Pharma Client's Vaccine Program | CI |
Sales 2021 | 338K 426K | Sales 2022 | 268K 338K | Capitalization | 87.45M 110M |
---|---|---|---|---|---|
Net income 2021 | -3M -3.78M | Net income 2022 | -5M -6.3M | EV / Sales 2021 | 200 x |
Net cash position 2021 | 8.06M 10.15M | Net cash position 2022 | 1.24M 1.56M | EV / Sales 2022 | 322 x |
P/E ratio 2021 |
-23.4
x | P/E ratio 2022 |
-17
x | Employees | 78 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 30.4% |
1 day | +15.98% | ||
1 week | +31.02% | ||
Current month | +32.24% | ||
1 month | +38.73% | ||
3 months | +95.17% | ||
6 months | +166.98% | ||
Current year | +108.09% |
Managers | Title | Age | Since |
---|---|---|---|
Heikki Lanckriet
CEO | Chief Executive Officer | 46 | 20-12-21 |
David John Roth
DFI | Director of Finance/CFO | 56 | 20-12-21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Joseph Fernández
BRD | Director/Board Member | 64 | - |
David John Roth
DFI | Director of Finance/CFO | 56 | 20-12-21 |
Director/Board Member | 53 | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-14 | 1,415 | +15.98% | 20,014 |
24-05-13 | 1,220 | +5.17% | 6,079 |
24-05-10 | 1,160 | +1.31% | 2,186 |
24-05-09 | 1,145 | +5.05% | 2,394 |
24-05-08 | 1,090 | +0.93% | 2,456 |
Delayed Quote London S.E., May 14, 2024 at 11:35 am EDT
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+108.09% | 196M | |
+29.03% | 48.16B | |
-0.10% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+11.48% | 25.59B | |
-22.74% | 18.96B | |
+9.06% | 12.92B | |
+30.01% | 12.03B | |
-1.51% | 11.77B |
- Stock Market
- Equities
- 4BB Stock